These patients may most likely benefit from preventive services like CM.
However, some meta-analyses have suggested that corticosteroid therapy may more likely benefit patients with severe septic shock that are vasopressor dependent [12, 15, 19].
However, some meta-analyses have suggested that corticosteroid therapy may more likely benefit patients with severe septic shock that are vasopressor dependent [ 12, 15, 19].
Yes, it is true that all treatments carry risk and the potential harm where there is minimal evidence of its effectiveness may outweigh the likely benefit.
Demonstration of likely benefit may be of particular importance when novel adjuvants with a limited safety profile, such as CPG 7909, are part of the clinical formulation.
For example, Dowsett et al. found that changes in Ki-67 in the neoadjuvant setting may be used to predict likely benefit (improved disease-free and overall survival) of AIs in the adjuvant setting [ 74], potentially expediting clinical development.
However, during the ongoing monitoring phase, when recurrence becomes less likely, patients may benefit more from their GPs' experience in managing chronic complications.
VeriStrat Poor patients may have an advantage when they are treated with chemotherapy instead of EGFR-TKIs, in contrast to the VeriStrat Good patients who may be likely to benefit from treatment with targeted therapy (Gregorc, 2009).
This does not imply that HMM professionals should be transformed into social scientists or visa versa, but rather that HHM research may be likely to benefit from a broader approach.
It is also evident, unfortunately, that the children who may be most likely to benefit are the least likely to attend ECEC, namely, children from low socioeconomic status (SES) families.
